Revised SPCs: Lorviqua (lorlatinib) 25 mg and 100mg film coated tablets

Data on the effect of lorlatinib on CYP2B6 substrates, CYP2C9 substrates, UGT substrates and P-glycoprotein substrates has been added to section 4.5, with advice on any monitoring required when used together.

Source:

electronic Medicines compendium